Mutation detail:
| Mutation site | S494R |
| Virus | SARS-CoV-2 |
Mutation level  |
Amino acid level |
| Gene/protein/region type | S |
| Gene ID | 43740568 |
| Country | USA |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | - |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | QHD43416.1 |
| Drug/antibody/vaccine | LY-CoV555-resistant,mAb_CB6-resistant,RENG10987-resistant,nAb_A19-61.1-resistant,nAb_A19-46.1-resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | Yes |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Spike glycoprotein |
| Uniprot protein ID | P0DTC2 |
| Protein length | 1273 amino acids |
| Protein description | Spike protein is one of the structural proteins of SARS-CoV-2. The monomeric protein consists of one large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail at C-terminus. It encompasses 22 glycosylation sites. S protein cleaves into two subunits namely S1 and S2 following receptor recognition. Receptor Binding Domain (RBD) in S1 subunit plays a major role in ACE2 receptor binding. |
Literature information:
| Pubmed ID | 34210892 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | Science |
| Title | Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants |
| Author | Lingshu Wang, Tongqing Zhou, Yi Zhang, Eun Sung Yang, Chaim A Schramm |
| Evidence | FIG 5, FIG 6 |